News
Calliditas Therapeutics Reports Data From Phase 2 Study Of Setanaxib In Combination With Pembrolizumab For Head And Neck Cancer
6 May 24
News
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
29 Apr 24
News, Intraday Update, Markets, Movers
Calliditas Announces NefIgArd Open Label Extension Results
24 Apr 24
News
Calliditas Therapeutics Presents Additional Data Analyses From Phase 3 NeflgArd Trial Of Nefecon In Primary IgA Nephropathy At ISN World Congress Of Nephrology 2024
18 Apr 24
News
Calliditas Receives Notice of Allowance for US Patent Application Covering Setanaxib in Cancer Treatment
8 Apr 24
Government, News, Regulations
Earlier Reported, Everest Medicines' Partner Calliditas Therapeutics Announces US FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon
12 Mar 24
Government, News, Regulations
Calliditas Bags An Additional Seven Year Orphan Drug Exclusivity Period For TARPEYO from the FDA
6 Mar 24
Government, News, Regulations
HC Wainwright & Co. Reiterates Buy on Calliditas Therapeutics, Maintains $50 Price Target
22 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Palo Alto Networks Issues Weak Outlook, Joins Teladoc Health, SolarEdge Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
21 Feb 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Calliditas Therapeutics Q4 EPADS $(0.06) Beats $(0.07) Estimate, Sales $42.41M Beat $35.86M Estimate
21 Feb 24
Earnings, News
Calliditas Therapeutics Announces That The U.S. Patent And Trademark Office Issued Patent #11896719, Entitled "New Pharmaceutical Compositions," On January 24, 2024 With Validity As Of Today, February 13, 2024
13 Feb 24
Biotech, News, General
Press releases
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
6 May 24
Press Releases
Calliditas Therapeutics' 2023 Annual Report Published
24 Apr 24
Small Cap, Press Releases
Calliditas Announces Positive NefIgArd Open Label Extension Results
24 Apr 24
Press Releases
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
18 Apr 24
Press Releases
Calliditas Therapeutics to Attend Conferences in April
9 Apr 24
Small Cap, Press Releases
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
8 Apr 24
Press Releases
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
8 Apr 24
Small Cap, Press Releases
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
11 Mar 24
Press Releases
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
6 Mar 24
Small Cap, Press Releases
Calliditas Therapeutics to Attend Investor Conferences in March
1 Mar 24
Small Cap, Press Releases
Calliditas Year-end report, January - December 2023
21 Feb 24
Earnings, Press Releases
Invitation to the presentation of Calliditas' Year-end report January - December 2023
14 Feb 24
Press Releases
Calliditas provides patent update
13 Feb 24
Press Releases